Under the terms of the private placement,
The closing of the private placement is expected to occur on
Following the closing,
Terms of the private placement can be found on a Form 8-K to be filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in
About
For updates and information on Waterlase® iPlus™ and laser dentistry, find
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding BIOLASE’s expectations regarding the closing of the private placement, use of proceeds and other non-historical facts. Forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, delays in satisfying or failure to satisfy closing conditions for the private placement, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described, from time-to-time, in the “Risk Factors” section of BIOLASE’s annual and quarterly reports filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170413005337/en/
President and Chief Executive Officer
hflynn@biolase.com
or
DresnerAllenCaron
212-691-8087
mmason@dresnerallencaron.com
or
rcaron@dresnerallencaron.com
or
949-474-4300
lhall@dresnerallencaron.com
Source:
Infosys meets 4Q profit forecasts
Research Reports on Medical Instruments & Supplies Equities — Baxter, DENTSPLY SIRONA, Skyline, and Hill-Rom
More Articles